iFAST Diagnostics is developing the iFAST One, an ultra-rapid antimicrobial susceptibility test system that leverages impedance flow cytometry to measure electrical properties of bacteria from positive blood culture samples. The platform can provide AST results in less than three hours and is priced comparably to the standard of care. The company received the UK Conformity Assessed (UKCA) mark for the system earlier this year. To support commercialization, iFAST closed a £5 million financing round and obtained a £2.1 million non-dilutive loan from Innovate UK. The new funding is earmarked to expand UK rollout, pursue EU regulatory approval, and accelerate regulatory and clinical programs in the US.

Total raised

$18M

Funding rounds

4

Latest round

Equity

Latest activity

May 2026